Dr. Wong was appointed as the Chief Technology Officer of New A Innovation Limited in June 2007 and currently Dr. Wong serves an honorary professor at the Department of Biochemistry of Chinese University of Hong Kong.

From 2002 to 2007, Dr. Wong was the Board Director and Chief Executive Officer of Advantek Biologics (HK) Limited. He has 40 years of experience in the development of protein therapeutics in Biotechnology industry. 

During his tenure as Acting Director at the New England Enzyme Center and Associate Professor at Tufts Medical School of Boston, Dr. Wong was responsible for the preparations of hundreds of biologics. Dr. Wong then co-founded Biopure Corporation (NASDAQ: BPUR), where he served as CTO and Senior Vice President. At Biopure, Dr. Wong was responsible for the development of Cephalosporin antibiotics and Hemoglobin-based oxygen carriers (artificial blood): Hemopure? and Oxyglobin?, as well as the strategic business ventures in the US and the Far East. Dr. Wong has also held a series of patents and been a licensor to a number of world-leading companies such as Roche (SWX: RO) and Teva (NASDAQ: TEVA). 

In 1992, the Executive Yuan of ROC named him Model of Overseas Chinese Young Entrepreneur. In 2001, Bunker Hill Community College of Boston, Massachusetts awarded Dr. Wong a President’s Distinguished Service Award for his extraordinary commitment for higher education in the Boston Asian community.